CTNI-59. MATRIX REGIMEN FOR NEWLY DIAGNOSED PRIMARY CNS DIFFUSE B-CELL LYMPHOMA

Abstract We report our experience treating 22 patients with newly diagnosed primary CNS diffuse B-cell lymphoma the MATRix regimen as reported by Ferreri, et al in 2016. The median age was 64 y (range 45-85); 10 were men and 12 women. Twenty had cerebral mass lesions, 1 a paraspinal mass, leptomeningeal disease. Treatment consisted of 4 cycles rituximab 375 mg/sq m (Days 1, 6); methotrexate 3.5 g/sq (Day 2); cytarabine 2 every h 3, 4); thiotepa 30 5). Patients without disease progression received carmustine 400 5 mg/kg followed autologous bone marrow transplantation. Four switched to after 6 only initial including thiotepa. Overall, 16 completed chemotherapy. Fourteen these went on transplantation; one patient early progression, no stem cells could be collected. Five (median 73 y; range 64-85 y) died 1-2 cycles. causes death neutropenic fever, septic thrombophlebitis, cardiac arrest. One who entire transplantation fungal pneumonia other 13 experienced serious acute toxicity. late developed symptomatic leukoencephalopathy. remain alive. Median OS for cohort is 663 days. These preliminary data suggest that safe highly effective setting. However, high incidence over 65 suggests may too toxic older individuals.